Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
218
-
Total 13F shares, excl. options
-
53.5M
-
Shares change
-
-853K
-
Total reported value, excl. options
-
$3.27B
-
Value change
-
-$23.4M
-
Put/Call ratio
-
0.38
-
Number of buys
-
102
-
Number of sells
-
-98
-
Price
-
$61.12
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q3 2020
269 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q3 2020.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 218 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.5M shares
of 62.7M outstanding shares and own 85.43% of the company stock.
Largest 10 shareholders include FMR LLC (7.8M shares), VANGUARD GROUP INC (4.52M shares), BlackRock Inc. (2.99M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.56M shares), D. E. Shaw & Co., Inc. (2.46M shares), GREAT POINT PARTNERS LLC (1.97M shares), JANUS HENDERSON GROUP PLC (1.62M shares), Bellevue Group AG (1.58M shares), JPMORGAN CHASE & CO (1.54M shares), and Invesco Ltd. (1.49M shares).
This table shows the top 218 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.